An antiviral drug originally developed to treat influenza reduces hospitalisation and death from Covid-19 by 50 per cent in patients recently infected with the virus, early trial results suggest. It ...

Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has ...

It’s always nice to get some unexpected good news. That’s especially true in COVID World, where the situation (Full hospitals! Thousands of deaths! Protests, stupidity and denial!) always seems ...

After showing a 50% reduction in the risk of hospitalization or death, Merck & Co. and Ridgeback Biotherapeutics’ molnupiravir looks on track to secure an FDA emergency use authorization and become a ...

In the search for effective COVID-19 treatments, many drugs failed to live up to their early promise. The antiviral molnupiravir performed well in trials, reducing hospitalizations and deaths among ...

TAMPA, Fla. — Over the last year, several drugs have either been developed or tested to treat coronavirus. Now there's another that's showing some promise. Molnupiravir is an antiviral drug in ...

The antiviral agent incorporates RNA-like building blocks into the genome of the virus. The United States recently secured 1.7 million doses of a compound that could help to treat Covid-19 patients.

If you buy through a BGR link, we may earn an affiliate commission, helping support our expert product labs. Researchers from the Georgia State University announced in early December the extremely ...

An experimental drug prevented half of severe coronavirus infections that would otherwise have sent people to the hospital, according to a study released Friday, offering promise that COVID-19 could ...

Last week, Merck and Ridgeback Biotherapeutics announced Phase 3 results of molnupiravir, an oral antiviral drug, in patients with mild-to-moderate Covid-19. In a trial that included more than 750 ...

A new Covid-19 therapy has completed its phase two human trial and the results are promising. Molnupiravir, developed by Ridgeback Biotherapeutics LP and Merck & Co., reached its endpoint objective of ...

An image showing mutations caused by NHC, the active component of molnupiravir to all genes and proteins of another pathogenic coronavirus, MHV. As much as people are justifiably excited about the ...